Lots of interesting abstracts and cases were submitted for TCTAP 2026. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge!
ABS20251120_0002
Clinical Outcomes, Complications, and Resource Utilization in Mechanical Circulatory Support-Assisted High-Risk PCI: A Five-Year Retrospective Study
By Hiteshi K.C. Chauhan
Presenter
Hiteshi K.C. Chauhan
Authors
Hiteshi K.C. Chauhan1
Affiliation
Fortis Healthcare Limited, India1
View Study Report
ABS20251120_0002
Hemodynamic Support
Clinical Outcomes, Complications, and Resource Utilization in Mechanical Circulatory Support-Assisted High-Risk PCI: A Five-Year Retrospective Study
Hiteshi K.C. Chauhan1
Fortis Healthcare Limited, India1
Background
High-riskpercutaneous coronary intervention (HR-PCI) often requires mechanicalcirculatory support (MCS) to maintain hemodynamic stability during complexrevascularization. In resource-limited settings, selective use of devices suchas the intra-aortic balloon pump (IABP), Impella, and venoarterialextracorporeal membrane oxygenation (VA-ECMO) offers a practical strategy formanaging high-risk patients. This study evaluates clinical outcomes, proceduralcomplications, and resource utilization associated with MCS-assisted HR-PCI ina single tertiary care center over five years.
Methods
We conducted aretrospective analysis of all patients who underwent HR-PCI with any form ofMCS between January 2020 and October 2025. Data were obtained frominstitutional electronic health records and included baseline characteristics,type of MCS used, procedural success, periprocedural complications, andin-hospital outcomes. MCS modalities included IABP, Impella, and VA-ECMO.Resource utilization metrics included intensive care unit (ICU) length of stay,total hospital stay, and 30-day readmission.
Results
A total of 140patients underwent MCS-assisted HR-PCI during the study period. IABP was usedin approximately 25% of cases, Impella in 3–4 patients annually, and VA-ECMO inone patient. In-hospital mortality was 6.4%. Major bleeding (BARC 3–5) occurredin 3% of patients, and vascular access complications occurred in 2%.Periprocedural myocardial infarction occurred in 8%. Acute kidney injurydeveloped in 11% of patients, with 4.4% requiring dialysis. Device-relatedhemolysis was rare (0.2%). Stroke occurred in 2.8% of cases. Mean ICU length ofstay was 4 days, mean total hospital stay was 8 days, and the 30-dayreadmission rate was 7%.
Conclusion
In this five-year single-center experience,MCS-assisted HR-PCI demonstrated favorable procedural and in-hospital outcomeswith low rates of major complications. Despite limited access to advancedsupport devices, structured and selective MCS utilization—predominantly withIABP—supported the safe performance of HR-PCI in a resource-constrainedenvironment. These findings reinforce the feasibility and safety of MCS use incomplex PCI and highlight opportunities to optimize peri-procedural managementin high-risk populations.